Sunday 18 October 2026
Export LTGO’s income statement to Excel — free account
Latigo Biotherapeutics Inc
LTGO
Insiders bought in the last twelve months.
13.98
0.78
−5.28%
Follow LTGO
| Jun '26 | Dec '25 | Jun '25 | |
|---|---|---|---|
Current Ratio |
1.15 | 4.00 | — |
Net Debt/EBITDA |
2.14 | 0.00 | 0.00 |
Debt/Assets |
0.00% | 0.00% | — |
Debt/Equity |
0.00 | 0.00 | — |
Operating CF/Net income |
0.00 | — | 0.00 |
Interest Coverage |
(102.82) | — | — |
Research and Development Expense of Revenue |
0.00% | — | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | — | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | — |
Free Cash Flow per Share |
0.00 | — | 0.00 |
Cash per Share |
59.03 | 0.00 | 0.00 |
Shareholders Equity per Share |
13.37 | 0.00 | 0.00 |
Interest Debt per Share |
0.00 | — | 0.00 |
Book value per Share |
13.37 | 0.00 | 0.00 |
| Other line items | |||
Quick Ratio |
1.07 | 3.77 | — |
Revenue per Share |
0.00 | — | 0.00 |
Operating CF per Share |
0.00 | — | 0.00 |
Capex per Share |
0.00 | — | 0.00 |
Working Capital |
7.62 | 55.38 | — |
Net Current Asset Value |
6.94 | 55.22 | — |
Columns are period end dates · fundamentals updated 29 Sep 2026